The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q3 2023 call → NO我们根据提供的财报电话会议记录,判断是否存在一个明确的、公司特定的疑虑,并且本期的实际运营证据是否明显反驳了该疑虑。 首先,寻找疑虑。在电话会议中,分析师和公司管理层多次提到FDA对De Novo申请的拒绝,以及关于比较组(comparator)的争议。这似乎是当前的主要问题,但这是否是一个“长期存在的疑虑”?从记录看,FDA的拒绝发生在2023年9月,而本次电话会议是2023年11月,所以这是近期事件,但管理层在讨论中提到了他们之前提交申请,并期望获得批准,但被拒绝。这更像是一个新出现的挫折,而不是长期存在的疑虑。然而,分析师的问题(如Anthony Vendetti和Kemp Dolliver)都围绕FDA的决定和未来路径,这可能是投资者关注点,但并非“长期存在的疑虑”如“公司能否盈利”或“产品是否有需求”。 另一个可能的疑虑是财务方面:公司净亏损,现金减少,但管理层提到成本削减和现金利用。分析师没有直接质疑盈利能力,但公司本身在亏损。然而,电话会议中并没有分析师明确表达“怀疑公司能否盈利”或“产品需求不足”的疑虑。相反,管理层强调了销售增长(11%的产品销售增长)和独立研究。 再考虑“依赖单一客户”或“市场”等。公司提到Terumo协议结束导致收入下降,但管理层说被产品销售增长部分抵消。这可能是疑虑,但分析师没有直接问。 最明显的疑虑可能是关于FDA批准的不确定性,以及这如何影响公司前景。但这是否是“长期存在的”?从记录看,公司之前提交了De Novo申请,期望获得批准,但被拒绝,现在上诉。这似乎是当前事件,而不是长期疑虑。然而,管理层在回答中提到了“我们相信”等,但并没有用实际运营证据来反驳,而是计划未来提交。 另一方面,管理层提到了实际销售增长、独立研究、新分销商等,这些是实际发生的。但疑虑是否被这些证据反驳?如果疑虑是“FDA批准受阻会影响销售”,那么管理层说销售仍在增长,这确实反驳了。但疑虑本身是否在电话会议中被明确表达为长期存在的?分析师的问题更多是询问下一步,而不是表达怀疑。 再仔细看:在Q&A中,Anthony Vendetti问“即使FDA拒绝,ProSense仍在美国获批,请提醒我们目前批准的适应症”,这似乎是在确认现状,而不是表达疑虑。Kemp Dolliver问关于比较组的问题,以及重新提交的时间。这些是具体问题,但并非“长期疑虑”。 或许疑虑是“公司能否在FDA拒绝后继续生存或增长”?但管理层用销售增长和独立研究来回应,这确实是用实际证据反驳。 然而,根据指令,疑虑必须是“公司特定的,且明显在电话会议中体现,如分析师反复提及,管理层承认”。这里分析师反复提及FDA问题,但这是新事件,不是长期存在的。另外,管理层在开场就提到“我们相信”等,但并没有明确说“投资者担心什么”。 另一个角度:公司亏损,现金减少,但管理层说成本削减,确保2024年目标。这可能是疑虑,但分析师没有直接问。 或许疑虑是“公司依赖单一产品ProSense,而FDA拒绝会影响其前景”?但管理层用销售增长来反驳。 我认为最接近的疑虑是“FDA批准的不确定性”,但这不是长期存在的,而是本季度发生的。而且管理层用实际销售增长来回应,但销售增长是整体,并非专门针对FDA拒绝后的情况。 再考虑:管理层提到“我们相信上诉会成功”,这是希望,不是实际证据。但销售增长是实际证据。 然而,指令要求“当前时期的实际活动”反驳疑虑。这里销售增长是实际活动,但疑虑是FDA批准,销售增长并不直接反驳FDA批准问题,因为销售增长可能来自其他适应症或地区。 或许疑虑是“公司能否实现盈利”,但管理层没有直接回应,只是说成本削减。 我认为没有明确的长期疑虑被识别。电话会议中主要讨论的是FDA拒绝和上诉,这是新事件,不是长期存在的。分析师的问题更多是询问下一步,而不是表达怀疑。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.